{"id":"ac-p-tec-ac-tc-tch-cef-tac-caf","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The regimen appears to be a combination of chemotherapy drugs (likely including anthracyclines, taxanes, and/or fluoropyrimidines based on the abbreviations) used in oncology. These agents work through different mechanisms—some intercalate DNA, others disrupt microtubules—to achieve synergistic cytotoxic effects against rapidly dividing cancer cells. The specific combination and dosing would be tailored to the cancer type being treated.","oneSentence":"This is a chemotherapy regimen combining multiple cytotoxic agents to treat cancer by damaging DNA and inhibiting cell division.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:04.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not clearly defined from abbreviations alone)"}]},"trialDetails":[{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["1.AC(doxorubicin/cyclophosphamide)-P(paclitaxel)","2.TEC(docetaxel/epirubicin/cyclophosphamide)","3.AC(doxorubicin/cyclophosphamide)-T(docetaxel)","4.TC(docetaxel/cyclophosphamide)","5.TCH(docetaxel/carboplatin/trastuzumab)"],"phase":"phase_3","status":"active","brandName":"AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF","genericName":"AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF","companyName":"Shandong Cancer Hospital and Institute","companyId":"shandong-cancer-hospital-and-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a chemotherapy regimen combining multiple cytotoxic agents to treat cancer by damaging DNA and inhibiting cell division. Used for Cancer (specific indication not clearly defined from abbreviations alone).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}